Hormonal
GLP-1 receptor agonists (semaglutide, tirzepatide, survodutide, retatrutide) promote resolution of metabolic dysfunction-associated steatohepatitis (MASH) and improve liver fibrosis in patients with MASLD/MASH.
If you have MASH or MASLD, GLP-1 RAs like semaglutide and tirzepatide can significantly improve liver health, resolving MASH in many patients and improving fibrosis. These benefits are in addition to their weight loss and cardiovascular benefits. Discuss these options with your liver specialist or primary care provider.
semaglutide 2.4 mg weekly achieved MASH resolution in 63% of participants versus 34% in the placebo group... Tirzepatide... demonstrated MASH resolution in 44–62% of participants... Survodutide... was shown to achieve MASH improvement in 43–62% and fibrosis improvement in 34–36% of participants
Why this rating
Based on phase 2 and 3 trials showing histologic improvement, but long-term outcomes and formal approvals are still evolving.
Source
Beyond Diabetes: A Review of Emerging Indications for Glucagon-Like Peptide-1 Receptor Agonists
Lucianne West et al. · Reviews in Cardiovascular Medicine · 2026
DOI 10.31083/rcm44528
More from this paper
- GLP-1 receptor agonists (specifically semaglutide 2.4 mg and tirzepatide) produce significant weight loss (14.9-20.9%) and improve cardiometabolic risk factors in adults with overweight or obesity, regardless of diabetes status.Strong
- GLP-1 receptor agonists improve cardiovascular outcomes in patients with atherosclerotic cardiovascular disease (ASCVD) and heart failure with preserved ejection fraction (HFpEF), but may increase heart failure hospitalization risk in patients with heart failure with reduced ejection fraction (HFrEF).Strong
- GLP-1 receptor agonists provide renal benefits, including reduced albuminuria and slower eGFR decline, in patients with type 2 diabetes and chronic kidney disease, independent of glycemic control.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →